Approved Drug Label (PDF)
5
Warnings and Precautions
5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Additions and/or
revisions underlined:
…REXULTI is not
approved for the treatment of patients with dementia-related psychosis without
agitation associated with dementia due to Alzheimer’s disease [see Boxed
Warning,
Warnings and Precautions (5.3)].
5.14 Potential for Cognitive and Motor Impairment
Additions and/or revisions underlined:
…
In the 12-week
placebo-controlled, fixed-dose clinical studies in patients (51 to 90 years of
age) with agitation associated with dementia due to Alzheimer’s disease, somnolence
(including sedation) was reported in 3% of patients treated with REXULTI
compared to 1% of patients treated with placebo.
…
5.3 Cerebrovascular Adverse Reactions Including Stroke in Elderly Patients with Dementia- Related Psychosis
Additions and or revisions underlined:
In
placebo-controlled trials in elderly patients with dementia, patients
randomized to risperidone, aripiprazole, and olanzapine had a higher incidence
of stroke and transient ischemic attack, including fatal stroke. REXULTI is not
approved for the treatment of patients with dementia-related psychosis without
agitation associated with dementia due to Alzheimer’s disease [see Boxed
Warning,
Warnings and Precautions (5.1)].
5.4 Neuroleptic Malignant Syndrome (NMS)
Additions and/or revisions underlined:
Neuroleptic Malignant Syndrome (NMS), a
potentially fatal symptom complex, has been reported in association with
administration of antipsychotic drugs, including REXULTI.
Clinical
manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status,
and evidence of autonomic instability (irregular pulse or blood pressure,
tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may
include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and
acute renal failure.
If NMS is suspected, immediately
discontinue REXULTI and provide intensive symptomatic treatment and monitoring.
5.5 Tardive Dyskinesia
Additions and/or revisions underlined:
…
The risk of tardive dyskinesia and the
likelihood that it will become irreversible appear to increase as the duration
of treatment and the cumulative dose increases. The syndrome can develop
after relatively brief treatment periods, at low doses. It may also occur after
discontinuation of treatment.
…
5.6 Metabolic Changes
Extensive additions and/or revisions,
please refer to label.
5.9 Orthostatic Hypotension and Syncope
Additions and/or
revisions underlined
Atypical antipsychotics cause orthostatic
hypotension and syncope. Generally, the risk is greatest during initial dose
titration and when increasing the dose. In the short-term, placebo-controlled
clinical studies of REXULTI plus ADT in adult patients with MDD, the incidence
of orthostatic hypotension-related adverse reactions in REXULTI plus
ADT-treated patients compared to placebo plus ADT-treated patients included: dizziness
(2% versus 2%) and orthostatic hypotension (0.1% versus 0%). In the
short-term, placebo-controlled clinical studies of REXULTI in adult patients
with schizophrenia, the incidence of orthostatic hypotension-related adverse
reactions in REXULTI-treated patients compared to placebo patients included:
dizziness (2% versus 2%), orthostatic hypotension (0.4% versus 0.2%), and
syncope (0.1% versus 0%). In 12-week, placebo- controlled clinical studies
of REXULTI in patients with agitation associated with dementia due to
Alzheimer’s disease, the incidence of orthostatic hypotension-related adverse
reactions in patients treated with REXULTI compared to patients treated with
placebo included: dizziness (3% versus 3%), orthostatic hypotension (1% versus
1%), and syncope (0.2% versus 0.8%).
…
6
Adverse Reactions
6.1 Clinical Trials Experience
Extensive
additions and/or revisions, please refer to label.
8
Use in Specific Populations
8.5 Geriatric Use
Additions and/or revisions underlined:
Antipsychotic drugs increase the risk of death in
elderly patients with dementia-related psychosis. REXULTI is not approved for
the treatment of patients with dementia-related psychosis [see Boxed Warning, Warnings and Precautions (5.1)].
Adjunctive Treatment of Major Depressive Disorder
(MDD) and Schizophrenia
Of the total number of REXULTI-treated patients in
the clinical studies for the adjunctive therapy to antidepressants for MDD and
for schizophrenia, 248 (3%) were 65 years of age and older (which included 45
(18%) patients who were 75 years of age and older). Clinical studies of REXULTI in these patients did not include sufficient
numbers of patients 65 years of age and older to determine whether
they respond differently from younger adult patients. In general, dosage
selection for the treatment of MDD or schizophrenia in a geriatric patient
should be cautious, usually starting at the low end of the dosing range,
reflecting the greater frequency of decreased hepatic, renal, and cardiac
function, concomitant diseases, and other drug therapy.
Agitation Associated with Dementia Due to
Alzheimer’s Disease
The total number of REXULTI-treated patients 65
years of age and older in the clinical studies for agitation associated with dementia due to Alzheimer’s disease (Studies 6 and 7) was 448
(86%) including 170 (33%) patients 65 to 74 years of age, 228 (44%) patients 75
to 84 years of age, and 50 (10%) patients 85 years of age and older [see Clinical Studies (14.3)
In clinical studies of REXULTI for the treatment of agitation
associated with dementia due to Alzheimer’s disease did not include
sufficient numbers of younger adult patients to determine if patients 65 years
of age and older respond differently than younger adult patients.
8.7 Hepatic Impairment
Additions and/or revisions underlined:
The maximum recommended dosage in patients with
moderate to severe hepatic impairment (Child-Pugh score greater than or equal
to 7) is lower than those with mild hepatic impairment and those with normal
hepatic function [see Dosage and
Administration (2.4)]. Patients with moderate to severe hepatic
impairment generally had higher exposure to brexpiprazole than patients with
normal hepatic function [see Clinical Pharmacology (12.3)]. Greater
exposure may increase the risk of REXULTI-associated adverse reactions
Approved Drug Label (PDF)
5
Warnings and Precautions
5.6 Metabolic Changes
Extensive changes; please refer to
label
6
Adverse Reactions
6.1 Clinical Trials Experience
Additions and/or revisions underlined:
Other Adverse
Reactions Observed during
the Premarketing Evaluation of REXULTI
Other adverse
reactions (greater than or equal to
1% frequency and greater than placebo) within the short-term, placebo-controlled trials in adult patients
with MDD and schizophrenia are shown below. The following listing does not include adverse reactions: 1) already
listed in previous
tables or elsewhere
in the labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have clinically significant implications, or 5) which occurred
at a rate equal to or less than placebo.
Eye Disorders: Vision Blurred
Gastrointestinal Disorders: Nausea, Dry Mouth, Salivary Hypersecretion, Abdominal Pain, Flatulence
Infections and Infestations: Urinary Tract Infection
Investigations: Blood Prolactin Increased
Musculoskeletal and Connective Tissue Disorders: Myalgia
Psychiatric Disorders: Abnormal Dreams, Insomnia
Skin and Subcutaneous Tissue
Disorders: Hyperhidrosis Pediatric Patients (13 to 17 years of age)
In an on-going,
2 year, open-label study in pediatric
patients 13 to 17 years of age with schizophrenia, in which safety was assessed in 194 patients of which 140 received REXULTI for at least 6 months.
Adverse reactions reported in clinical
studies for this age group were generally
similar to those observed in adult patients.
8
Use in Specific Populations
8.4 Pediatric Use
Additions and/or revisions underlined:
Schizophrenia
Safety and effectiveness of
REXULTI for treatment
of schizophrenia have been established in
pediatric patients 13 years of age and older. Use of REXULTI
in this population is supported
by evidence from adequate and well-controlled studies in adults with schizophrenia, pharmacokinetic data from adults and pediatric patients,
and safety data in pediatric patients 13 to 17 years of age [see Warnings
and Precautions (5.6), Adverse Reactions (6.1), Clinical Pharmacology (12.3)].Major Depressive Disorder
Safety and effectiveness in pediatric
patients with major depressive disorder have not been established. Antidepressants increased the risk of suicidal thoughts and behaviors
in pediatric patients [see Boxed Warning, Warnings and Precautions (5.2)].
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
MEDICATION GUIDE
Extensive changes; please refer to
label
Approved Drug Label (PDF)
5
Warnings and Precautions
Neuroleptic Malignant Syndrome (NMS)
(Additions and/or
revisions underlined)
A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including REXULTI.
Tardive Dyskinesia
(Additions and/or revisions
underlined)
The effect that symptomatic suppression has upon the long-term course of tardive
dyskinesia is unknown.
6
Adverse Reactions
Postmarketing Experience
(Newly added section)
The following adverse reaction has been identified during post-approval use of REXULTI.
Because these reactions are reported
voluntarily from a population of uncertain size, it is not always
possible to reliably
estimate their frequency or establish a causal
relationship to drug exposure.
Nervous System disorders: Neuroleptic Malignant Syndrome
Approved Drug Label (PDF)
5
Warnings and Precautions
5.7 Pathological Gambling and Other Compulsive Behaviors
Newly
added subsection:
Post-marketing case reports suggest that
patients can experience intense urges, particularly for gambling, and the
inability to control these urges while taking REXULTI. Other compulsive urges,
reported less frequently, include: sexual urges, shopping, eating or binge
eating, and other impulsive or compulsive behaviors. Because patients may not
recognize these behaviors as abnormal, it is important for prescribers to ask
patients or their caregivers specifically about the development of new or
intense gambling urges, compulsive sexual urges, compulsive shopping, binge or
compulsive eating, or other urges while being treated with REXULTI. In some
cases, although not all, urges were reported to have stopped when the dose was
reduced or the medication was discontinued. Compulsive behaviors may result in
harm to the patient and others if not recognized. Consider dose reduction or
stopping the medication if a patient develops such urges.
6
Adverse Reactions
Addition
of the following:
17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)
PATIENT COUNSELING INFORMATION
Addition
of the following:
Pathological Gambling and Other Compulsive
Behaviors
Advise patients and their caregivers of
the possibility that they may experience compulsive urges to shop, intense
urges to gamble, compulsive sexual urges, binge eating and/or other compulsive
urges and the inability to control these urges while taking REXULTI. In some
cases, but not all, the urges were reported to have stopped when the dose was
reduced or stopped.
Approved Drug Label (PDF)
5
Warnings and Precautions
5.9 Falls
(Newly added subsection)
Antipsychotics, including REXULTI, may cause somnolence,
postural hypotension, motor and sensory instability, which may lead to falls and,
consequently, fractures or other injuries. For patients with diseases, conditions,
or medications that could exacerbate these effects, complete fall risk assessments
when initiating antipsychotic treatment and recurrently for patients on long-term
antipsychotic therapy.
Approved Drug Label (PDF)
5
Warnings and Precautions
5.10 Body Temperature Dysregulation
Atypical
antipsychotics may disrupt the body’s ability to reduce core body temperature.
Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic
medications may contribute to an elevation in core body temperature; use
REXULTI with caution in patients who may experience these conditions. (revised)
5.12 Potential for Cognitive and Motor Impairment
REXULTI, like other antipsychotics, has the
potential to impair judgment, thinking, or motor skills. In 6-week,
placebo controlled clinical trials in patients with MDD, somnolence (including
sedation and hypersomnia) was reported in 4% for REXULTI+ADT-treated patients
compared to 1% of placebo+ADT patients.
In
6-week, placebo-controlled clinical trials in patients with schizophrenia,
somnolence (including sedation and hypersomnia) was reported in 5% of
REXULTI-treated patients compared to 3% of placebo-treated patients.
Patients
should be cautioned about operating hazardous machinery, including motor
vehicles, until they are reasonably certain that REXULTI therapy does
not affect them adversely.
5.3 Cerebrovascular Adverse Reactions Including Stroke in Elderly Patients with Dementia-Related Psychosis
In
placebo-controlled trials in elderly subjects with dementia, patients
randomized to risperidone, aripiprazole, and olanzapine had a higher incidence
of stroke and transient ischemic attack, including fatal stroke. REXULTI is not
approved for the treatment of patients with dementia-related psychosis.
(revised)
5.4 Neuroleptic Malignant Syndrome (NMS)
5.6 Metabolic Changes
Hyperglycemia and Diabetes
Mellitus
Dyslipidemia
Major Depressive Disorder
In the long-term, open-label depression
studies, shifts in baseline fasting cholesterol from normal to high were
reported in 9% (total cholesterol), 3% (LDL cholesterol), and shifts in
baseline from normal to low were reported in 14% (HDL
cholesterol) of patients taking REXULTI… (revision
underlined)
Weight Gain
5.7 Leukopenia, Neutropenia, and Agranulocytosis
Leukopenia
and neutropenia have been reported during treatment with antipsychotic agents.
Agranulocytosis (including fatal cases) has been reported with other
agents in this class. (revised)
In patients with a pre-existing low WBC or ANC or a
history of drug-induced leukopenia or neutropenia, perform a
complete blood count (CBC) frequently during the first few months of therapy.
(revision underlined)
5.8 Orthostatic Hypotension and Syncope
Atypical antipsychotics cause orthostatic
hypotension and syncope. Generally, the risk is greatest during initial dose
titration and when increasing the dose. In the short-term, placebo-controlled
clinical studies of REXULTI+ADT… revision underlined)
Orthostatic
vital signs should be monitored in patients who are vulnerable to hypotension,
(e.g., elderly patients, patients with dehydration, hypovolemia, concomitant
treatment with antihypertensive medication, patients with known cardiovascular
disease (history of myocardial infarction, ischemic heart disease, heart
failure, or conduction abnormalities), and patients with cerebrovascular
disease. REXULTI has not been evaluated in patients with a recent history of
myocardial infarction or unstable cardiovascular disease. Such patients were
excluded from pre-marketing clinical trials. (revised)
5.9 Seizures